Results 111 to 120 of about 8,086 (190)

Prostate cancer in Asia: a collaborative report [PDF]

, 2014
published_or_final_versio
Chen, R, Chinese Prostate Cancer Consortium, Ren, S, Sun, Y, Yiu, MK   +4 more
core   +1 more source

Comprehensive Analysis of Genomic Variations in Pancreatic Adenocarcinoma by Race

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Purpose Racial disparities in pancreatic ductal adenocarcinoma (PDAC) incidence and outcomes persist even after adjusting for access to care and treatment received, suggesting a role for tumor‐specific molecular factors. This study aimed to compare the mutational landscape of PDAC tumor samples across racial groups using a large, diverse ...
Mohamad El Moheb, Kaelyn C. Cummins, Chengli Shen, Elio R. Bitar, Susan J. Kim, Mackenzie M. Mayhew, Hongji Zhang, Russell G. Witt, Samantha M. Ruff, Allan Tsung   +9 more
wiley   +1 more source

The molecular and cellular origin of human prostate cancer [PDF]

, 2016
Prostate cancer is the most commonly diagnosed male malignancy. Despite compelling epidemiology, there are no definitive aetiological clues linking development to frequency.
Abate-Shen, Abrahamsson, Adler, Al-Hajj, Albini, Ammirante, An, An, Anderson, Anderson, Antonarakis, Ao, Armitage, Baca, Baker, Bapat, Barbieri, Barker, Barsky, Beck, Beltran, Ben-Neriah, Bergh, Bernstein, Berry, Bethel, Birkeland, Birnie, Blackwood, Bonnet, Borel, Bostwick, Bostwick, Boysen, Briganti, Bubendorf, Burkhardt, Caini, Cairns, Calabrese, Cancer Research UK, Carreira, Cesare, Chakkalakal, Chapman-Rothe, Chen, Cheshier, Choi, Chua, Clevers, Cloos, Cohen, Cohen, Collins, Collins, Conboy, Cooper, Culig, Culig, Cunha, Cunha, Dan Robinson, Das, Dawson, De Marzo, De Marzo, Dehm, Deng, Dermer, Ding, Don-Doncow, Donaldson, Dong, Ebelt, Eggener, Eminaga, Epstein, Eramo, Essers, Fang, Fassi Fehri, Fearon, Feinberg, Feng, Fialkow, Figueiredo, Foudi, Frame, Frame, Frame, Franco, Franks, Gan, Gannon, Gao, Gendrel, Gerlinger, Germann, Ghajar, Gibbs, Gimelbrant, Gleason, Gleave, Goardon, Goldstein, Gong, Goodwin, Gotay, Grasso, Grasso, Greaves, Grisanzio, Gundem, Guo, Gupta, Gurel, Guryanova, Gutierrez-Arcelus, Haapala, Haas, Haffner, Haffner, Haffner, Haffner, Hahn, Hall, Hall, Han, Hanahan, Hansel, He, Heaphy, Hecht, Heer, Herawi, Hermann, Hernandez, Heydt, Hjelmeland, Hong, Hong, Hovelson, Hrbacek, Hu, Huels, Huggins, Hurt, Hurt, Hägglöf, IACR, Iliopoulos, Iliou, Inaguma, Isaacs, Jafari, Jiao, Jin, John R. Packer, Johnston, Jones, Jones, Joseph, Karanika, Karantanos, Karthaus, Ke, Ke, Keller, Kelly, Kiel, Kim, Kooistra, Korpal, Kouzarides, Kovtun, Kreso, Krieger, Krieger, Kroon, Kulac, Kunderfranco, Lang, Lang, Lanie, Lapointe, Lark, Lavery, Lee, Lee, Leong, Leongamornlert, Li, Li, Li, Li, Lilja, Lin, Lin, Ling, Liu, Lo, Loeb, Luedeke, Lukacs, Ma, Mahmud, Maini, Maitland, Maitland, Maitland, Maitland, Mani, Marinov, Martin, Matsui, Meeker, Mehrotra, Menon, Merok, Metsalu, Metzger, Meyer, Michaud, Miyamoto, Mohan, Mounir, Munger, Nag, Nag, Nakai, Nakashima, Navarro, Nelson, Network, Nonn, Nonomura, Norman J. Maitland, Norrish, Nowell, O'Callaghan, O'Sullivan, Ohm, Olumi, Osman, Ousset, Park, Pascale, Patel, Patel, Patra, Patrawala, Patrawala, Pellacani, Penney, Perner, Perner, Perry, Peto, Pierce, Platz, Polson, Potten, Potter, Prince, Pritchard, Putzi, Qin, Rajan, Rando, Rane, Rane, Raval, Reik, Ricci-Vitiani, Ricci-Vitiani, Rich, Richardson, Riley, Risbridger, Robinson, Rodriguez, Rosa Mendoza, Ross-Adams, Roth, Ruska, Rutella, Sack, Sakr, Schiewer, Schober, Schroeder, Sfanos, Sfanos, Sfanos, Sfanos, Sharma, Sharma, Shen, Shibata, Shinohara, Shiozawa, Singh, Singh, Slaughter, Smith, Sneddon, Sommerfeld, Song, Song, Steinhauser, Stewart, Strand, Strasner, Stratton, Strickler, Sugimura, Suzuki, Tan, Tan, Tang, Taplin, Taylor, Tepper, Thompson, Ting, Ting, Toh, Tollervey, Tomasetti, Tomasetti, Tomasetti, Tomlins, Tomlins, Tomlinson, Tomlinson, Trock, True, Trumpp, Tuxhorn, Twillie, Urquidi, Ushijima, Valastyan, Van, Van Asperen, Vincent, Vindrieux, Visakorpi, Visvader, Vogelstein, Vral, Wang, Wang, Wang, Wang, Wang, Wang, Watt, Weinberger, Whitaker, Wild, Williams, Wilson, Woo, Wymenga, Xiang, Xiang, Xu, Yachida, Yamamoto, Yatabe, Yoshimoto, Yu, Zambrano, Zhang, Zhang, Zhang   +376 more
core   +1 more source

Nicotinic Acetylcholine Receptor Pathways in Cancer: From Psychiatric Clues to Therapeutic Opportunities

Cancer Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background The prevalence of cancer poses significant challenges to treatment, largely because of drug resistance along with other side effects. Current studies have been investigating the growth factors more than other biologic tumor features, such as neurobiologic features.
Mohammad Hossein Azadi, Pouya Pazooki, Soheila Ajdary, Hamed Shafaroodi   +3 more
wiley   +1 more source

Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy

Molecular and Cellular Endocrinology, 2018
Prostate cancer (PCa) is the most common malignancy detected in males and the second most common cause of cancer death in western countries. The development of the prostate gland, is finely regulated by androgens which modulate also its growth and function.
Zoni, Eugenio, Karkampouna, Sofia, Thalmann, George N., Kruithof-de Julio, Marianna, Spahn, Martin   +4 more
openaire   +3 more sources

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. [PDF]

, 2018
Purpose: Molecular characterization of prostate cancer, including The Cancer Genome Atlas, has revealed distinct subtypes with underlying genomic alterations.
Alshalalfa, Mohammed, Barbieri, Christopher E., Davicioni, Elai, Den, Robert B., Erho, Nicholas, Jenkins, Robert B., Karnes, R. Jeffrey, Klein, Eric A., Liu, Deli, Ross, Ashley E., Rubin, Mark A., Sboner, Andrea, Schaeffer, Edward M., Shoag, Jonathan, Spratt, Daniel E., Takhar, Mandeep, Tomlins, Scott A., Trock, Bruce   +17 more
core   +1 more source

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. [PDF]

, 2017
Androgen receptor (AR) signaling remains the major oncogenic pathway in prostate cancer (PCa). Androgen-deprivation therapy (ADT) is the principle treatment for locally advanced and metastatic disease.
Cucchiara, Vito, Evans, Christopher P, Gao, Allen C, Mirone, Vincenzo, Rosenfeld, Michael G, Yang, Joy C   +5 more
core   +2 more sources

CCL11 (eotaxin‐1): A new diagnostic serum marker for prostate cancer [PDF]

, 2012
BACKGROUND The recent recommendation of the U.S. Preventive Services Task Force against PSA‐based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to ...
Agarwal, Manisha, He, Chang, Macoska, Jill A., Siddiqui, Javed, Wei, John T.   +4 more
core   +1 more source

RELATIONSHIP BETWEEN THE EXPRESSION OF ERG/ PBOV1 PROTEINS AND LYMPH NODE METASTASIS AND MORPHOLOGICAL CHARACTERISTICS OF ACINAR ADENOCARCINOMA OF THE PROSTATE

Сибирский онкологический журнал, 2017
When examining prostate cancer, a great attention is currently paid to the study of specific molecular characteristics of the tumor. It has been found that TMPRSS2-ERG is the most common fusion gene in prostate cancer. The fusion between TMPRSS2 and ERG/
N. V. Bezgodova, S. V. Vtorushin, M. V. Zavyalova   +2 more
doaj   +1 more source

Lrf suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion [PDF]

, 2014
Lrf has been previously described as a powerful proto-oncogene. Here we surprisingly demonstrate that Lrf plays a critical oncosuppressive role in the prostate.
Ala, Ugo, Carver, Brett, Chen, Zhenbang, Cordon-Cardo, Carlos, Egia, Ainara, Gerald, William L., Gonzalez-Billalabeitia, Enrique, Kuo, Winston Patrick, Liu, Xue-Song, Lunardi, Andrea, Nardella, Caterina, Pandolfi, Pier Paolo, Shaffer, David R., Signoretti, Sabina, Taulli, Riccardo, Tay, Yvonne, Wang, Guocan, Webster, Kaitlyn A., Zhang, Jiangwen   +18 more
core   +1 more source